Oxford researchers are developing blood test predictors of vaccine efficacy

Reuters | Release: June 26, 2021 16:08:03 | Updated: June 26, 2021 20:22:04 Researchers at Oxford University said Thursday that they developed a method to predict the efficacy of the new COVID-19 vaccine based on blood tests, providing a shortcut for large-scale clinical trials that are becoming increasingly difficult to conduct. There is likely to be. After receiving the vaccine developed by AstraZeneca and the University of Oxford (now known as Vaxevria), the researchers examined the levels of antibodies in the blood of study participants to fight various viruses. By investigating which of these study volunteers later became infected with symptomatic COVID-19 and which did not, researchers can determine how powerful the other vaccines are based on their blood measurements. I came up with a model to predict. "This data can be used to estimate efficacy estimates for new vaccines that cannot be tested for large-scale efficacy," posted online Thursday and peered for future publication in scientific journals. Said in the paper submitted for review. Oxford researchers warned that more work would be needed to validate the model for many of the highly contagious new viral variants of concern. They did not examine the human body's primary weapon against infection, the so-called cell-mediated immune response, along with antibodies, but said it was more difficult to measure. "There is an urgent need to increase the supply of vaccines to the world, but it will take months to develop and approve new vaccines. We hope that the use of correlations between developers and regulators can speed up the process. "Masu," said a senior researcher at the Oxford Vaccine Group and the Oxford Vaccine Trials. Researchers and regulators around the world are working on such benchmarks, known as protection or surrogate endpoint correlation. This could allow delays in the race for a vaccine development to provide evidence of efficacy without conducting trials with tens of thousands of volunteers. These population trials have so far relied on participants to get sick in their normal lives in order to provide vaccine efficacy results. If the vaccination rate is already high and the virus is not widely distributed, it becomes a bigger challenge. Traditional clinical trials require more participants to obtain a placebo compared to those who have been vaccinated with the vaccine, and an ethical dilemma arises when approved shots are available. .. Pictures Credit

ExBulletin

Oxford researchers are developing blood test predictors of vaccine efficacy

Health

Oxford researchers are developing blood test predictors of vaccine efficacy

Related

Recent Posts

Add ExBulletin to your Home screen!